Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize ...

For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonist use is associated with a reduced risk for developing hematologic cancers compared with insulin and metformin use.

Preoperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is not associated with short-term postoperative ...

Discontinuation was defined as 60 days without any GLP-1 RA on hand. Reinitiation was defined as the first fill of any GLP-1 RA after discontinuation. Patients were followed for up to two years ...

Adding the glucagon-like peptide 1 receptor agonist (GLP-1 RA) liraglutide to standard therapy reduces the risk for recurrent stroke in patients with type 2 diabetes (T2D) and a minor acute ...

Depression risk for patients receiving GLP-1 RA was slightly higher than those receiving SGLT-2i and lower than those receiving DPP-4i.

Physicians should approach patients with empathy and be open to patients who are seeking out a compounded GLP-1 RA, Chen said. For example, before expressing concerns about potential harms ...

HealthDay News — For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic cancers compared ...

"This finding suggests that it may be beneficial to reassess the preoperative withholding guidelines for GLP-1 RAs." HealthDay News — Preoperative glucagon-like peptide-1 receptor agonist (GLP-1 ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use in patients with type 2 diabetes is linked to a reduced risk of developing certain hematologic cancers compared to insulin and metformin.